Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2025-04-01 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
关于“灵康转债”可选择回售的第六次提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the conditional repurchase (回售) of convertible bonds (灵康转债) by the company 灵康药业集团股份有限公司. It includes specific terms such as repurchase price, repurchase period, interest calculations, and procedures for bondholders to exercise their repurchase rights. The document is regulatory in nature, providing information about bondholder rights and company obligations under bond issuance rules and stock exchange regulations. It does not contain financial statements, management discussion, or audit information. It is not a report but an official announcement related to financing instruments and bondholder rights. Therefore, the document fits best under Capital/Financing Update (CAP). The document length is 2463 characters, which is sufficient for a detailed announcement but not a full financial report. Hence, the classification is CAP with high confidence.
2025-04-01 Chinese
关于“灵康转债”可选择回售的第五次提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the optional repurchase (回售) of convertible bonds ('灵康转债') issued by Lingkang Pharmaceutical Group Co., Ltd. It includes specific terms such as repurchase price, repurchase period, interest calculations, and procedural instructions for bondholders. The content focuses on a financing instrument (convertible bonds) and the company's obligations and options related to bond repurchase. There is no indication that this is a full financial report, audit report, or earnings release. It is not a regulatory certification or a simple announcement of a report publication. The document is a capital/financing update related to convertible bond repurchase rights and procedures, which fits the category of Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2025-03-31 Chinese
关于“灵康转债”可选择回售的第四次提示性公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the fourth reminder for the optional repurchase (回售) of its convertible bonds (灵康转债). It details the repurchase price, repurchase period, payment date, conditions triggering the repurchase right, and instructions for bondholders on how to exercise this right. The document includes regulatory references and specific dates but does not contain financial statements or comprehensive financial analysis. It is a notification about a capital/financing event related to convertible bonds, specifically about bondholders' rights to sell back bonds to the company. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories.
2025-03-28 Chinese
关于“灵康转债”可选择回售的第三次提示性公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the third reminder for the optional repurchase (回售) of its convertible bonds (灵康转债). It details the repurchase price, repurchase period, payment date, conditions triggering the repurchase right, and instructions for bondholders to exercise this right. The document references regulatory rules and bond issuance terms but does not contain financial statements or comprehensive financial data. It is a specific event announcement related to bond repurchase rights and procedures, not a financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as convertible bond repurchases.
2025-03-27 Chinese
关于“灵康转债”可选择回售的第二次提示性公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the optional repurchase (回售) of its convertible bonds (灵康转债). It details the repurchase price, repurchase period, payment date, conditions triggering the repurchase right, and instructions for bondholders to exercise this right. The document includes regulatory references and specific dates but does not contain financial statements or comprehensive financial analysis. It is a notification about a capital/financing event related to convertible bonds, specifically a bond repurchase option. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 2466 characters, which is consistent with an announcement rather than a full report.
2025-03-26 Chinese
关于“灵康转债”可选择回售的第一次提示性公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the first indicative notice of the optional repurchase (回售) of its convertible bonds (灵康转债). It details the repurchase price, repurchase period, payment date, conditions triggering the repurchase right, and instructions for bondholders to exercise this right. The document includes regulatory references and specific dates but does not contain financial statements or detailed financial analysis. It is a notification about a capital/financing event related to convertible bonds, specifically the bondholders' right to sell back bonds to the company under certain conditions. This fits the category of Capital/Financing Update (CAP). The document length is 2466 characters, which is relatively short but contains substantive information about financing terms rather than just announcing a report publication or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2025-03-25 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.